Emerging pharmacological strategies in the fight against cocaine addiction

Expert Opinion on Emerging Drugs

Volumn 11, Issue 1, 2006, Pages 91-98

  Sofuoglu, Mehmet ^a   Kosten, Thomas R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Cocaine; Pharmacotherapies

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ADRENERGIC RECEPTOR BLOCKING AGENT; AMANTADINE; AMPHETAMINE DERIVATIVE; BACLOFEN; CARVEDILOL; COCAINE VACCINE; DEXAMPHETAMINE; DISULFIRAM; DONEPEZIL; DOPAMINE BETA MONOOXYGENASE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE UPTAKE INHIBITOR; LABETALOL; METHADONE; MODAFINIL; NALTREXONE; NRP 104; PLACEBO; PROPRANOLOL; PSYCHOSTIMULANT AGENT; RTI 336; SERTRALINE; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VACCINE; VANOXERINE;

ALCOHOLISM; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; COCAINE DEPENDENCE; COGNITIVE THERAPY; CRIME; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; GABAERGIC SYSTEM; HUMAN; INFECTION RISK; METHADONE TREATMENT; NARCOLEPSY; REVIEW; SEIZURE; SHIFT WORKER; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP APNEA SYNDROME; SLEEP DISORDER; SYSTEMATIC REVIEW; VIOLENCE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BENZHYDRYL COMPOUNDS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; COCAINE-RELATED DISORDERS; DISULFIRAM; DOPAMINE; DOPAMINE AGENTS; DOPAMINE BETA-HYDROXYLASE; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GABA AGONISTS; GABA PLASMA MEMBRANE TRANSPORT PROTEINS; GAMMA-AMINOBUTYRIC ACID; HUMANS; NIPECOTIC ACIDS; PROPRANOLOL; RANDOMIZED CONTROLLED TRIALS; VACCINES;

EID: 33645120326     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.11.1.91     Document Type: Review

References (90)

1. BENOWITZ NL: Nicotine addiction. Prim. Care (1999) 26(3):611-631.
2. AMERICAN PSYCHIATRIC ASSOCIATION: DSM-IV. In: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Association, Washington, DC, USA (1994):886.
3. KLEBER HD: Pharmacologic treatments for heroin and cocaine dependence. Am. J. Addict. (2003) 12(2):S5-S18.
4. HEADING CE: Recent advances against substance abuse. IDrugs (2003) 6(7):681-687.
5. GRABOWSKI J, SHEARER J, MERRILL J, NEGUS SS: Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict. Behav. (2004) 29(7):1439-1464.
6. FERRI CP, GOSSOP M: Route of cocaine administration: patterns of use and problems among a Brazilian sample, Addict. Behav. (1999) 24(6):815-821.
7. BOOTH RE, KWIATKOWSKI CF, CHITWOOD DD: Sex related HIV risk behaviors: differential risks among injection drug users, crack smokers, and injection drug users who smoke crack. Drug Alcohol Depend. (2000) 58(3):219-226.
8. TYNDALL MW, CURRIE S, SPITTAL P et al.: Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. Aids (2003) 17(6):887-893.
9. KAYE S, DARKE S: Injecting and non-injecting cocaine use in Sydney, Australia: physical and psychological morbidity. Drug Alcohol Rev. (2004) 23(4):391-398.
10. LEXAU BJ, NELSON D, HATSUKAMI DK: Comparing i.v. and non-i.v. cocaine users. Characteristics of a sample of cocaine users seeking to participate in research. Am. J. Addict. (1998) 7(4):262-271.
11. CARTWRIGHT WS: Cocaine medications, cocaine consumption and societal costs. Pharmacoeconomics (2000) 18(4):405-413.
12. HENNESSY GO, DE MENIL V, WEISS RD: Psychosocial treatments for cocaine dependence. Curr. Psychiatry Rep. (2003) 5(5):362-364.
13. HIGGINS ST, BUDNEY AJ, BICKEL WK et al.: Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch. Gen. Psychiatry (1994) 51(7):568-576.
14. SIQUELAND L, CRITS-CHRISTOPH P: Current developments in psychosocial treatments of alcohol and substance abuse. Curr. Psychiatry Rep. (1999) 1(2):179-184.
15. PETRY NM, SIMCIC F Jr: Recent advances in the dissemination of contingency management techniques: clinical and research perspectives. J. Subst. Abuse Treat. (2002) 23(2):81-86.
16. MCGOVERN MP, CARROLL KM: Evidence-based practices for substance use disorders. Psychiatr. Clin. North Am. (2003) 26(4):991-1010.
17. BARDO MT: Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Crit. Rev. Neurobiol (1998) 12(1-2):37-67.
18. KOOB GF: Neural mechanisms of drug reinforcement. Ann. NY Acad. Sci. (1992) 654:171-191.
19. TZSCHENTKE TM, SCHMIDT WJ: Functional relationship among medial prefrontal cortex, nucleus accumbens, and ventral tegmental area in locomotion and reward. Crit. Rev. Neurobiol. (2000) 14(2):131-142.
20. MARKOU A, KOOB GF: Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology (1991) 4(1):17-26.
21. KOOB GF, CAINE SB, PARSON SL, MARKOU A, WEISS F: Opponent process model and psychostimulant addiction. Pharmacol. Biochem. Behav. (1997) 57(3):513-521.
22. ROTHMAN RB, BAUMANN MH, DERSCH CM et al.: Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse (2001) 39(1):32-41.
23. BREBNER K, CHILDRESS AR, ROBERTS DC: A potential role for GABA(B) agonists in the treatment of psychostimulant addiction. Alcohol Alcohol. (2002) 37(5):478-484.
24. COUSINS MS, ROBERTS DC, DE WIT H: GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend. (2002) 65(3):209-220.
25. DEWEY SL, MORGAN AE, ASHBY CR Jr et al.: A novel strategy for the treatment of cocaine addiction. Synapse (1998) 30(2):119-129.
26. VOLKOW ND, WANG GJ, FOWLER JS et al.: Enhanced sensitivity to benzodiazepines in active cocaine-abusing subjects: a PET study. Am. J. Psychiatry (1998) 155(2):200-206.
27. WOLF ME: The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog. Neurobiol. (1998) 54(6):679-720.
28. LEE B, TIEFENBACHER S, PLATT DM, SPEALMAN RD: Role of the hypothalamic-pituitary-adrenal axis in reinstatement of cocaine-seeking behavior in squirrel monkeys. Psychopharmacology (Berl) (2003) 168(1-2):177-183.
29. ROMIEU P, MARTIN-FARDON R, BOWEN WD, MAURICE T: Sigma 1 receptor-related neuroactive steroids modulate cocaine-induced reward. J. Neurosci. (2003) 23(9):3572-3576.
30. CHEFER VI, CZYZYK T, BOLAN EA et al.: Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine. J. Neurosci. (2005) 25(20):5029-5037.
31. 2 receptors and endocannabinoids mediates the effects of cocaine on striatal GABAergic transmission. Neuropsychopharmacology (2004) 29(8):1488-1497.
32. FORMAN LJ: The effect of cannabinoid receptor antagonism with SR141716A on antinociception induced by cocaine and the NMDA receptor antagonist, MK-801. Brain Res. Bull. (2003) 61(2):153-158.
33. HUGHES JC, COOK CC: The efficacy of disulfiram: a review of outcome studies. Addiction (1997) 92(4):381-395.
34. NAGENDRA SN, FAIMAN MD, DAVIS K et al.: Carbamoylation of brain glutamate receptors by a disulfiram metabolite. J. Biol. Chem. (1997) 272(39):24247-24251.
35. CARROLL K, ZIEDONIS D, O'MALLEY S et al.: Pharmacologic interventions for alcohol- and cocaine-abusing individuals: a pilot study of disulfiram versus naltrexone. Am. J. Addict. (1993) 2:77-79.
36. CARROLL KM, NICH C, BALL SA, MCCANCE E, ROUNSAVILE BJ: Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction (1998) 93(5):713-727.
37. GEORGE TP, CHAWARSKI MC, PAKES J et al.: Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol. Psychiatry (2000) 47(12):1080-1086.
38. PETRAKIS IL, CARROLL KM, NICH C et al.: Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction (2000) 95(2):219-228.
39. CARROLL KM, FENTON LR, BALL SA et al.: Efficacy of disulfiram and cognitive-behavioral therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch. Gen. Psychiatry (2004) 61(3):264-272.
40. MCCANCE-KATZ EF, KOSTEN TR, JATLOW P: Disulfiram effects on acute cocaine administration. Drug Alcohol Depend. (1998) 52(1):27-39.
41. SCHOTTENFELD RS, CHAWARSKI MC, GEORGE TPA, CUBELLS JF: Pharmacogenetics of disulfiram for cocaine treatment: Role of DBH genotype. Presented at: The 66th Annual CPDD Meeting. San Juan, Puerto Rico (2004).
42. OLIVETO A, POLING J, PRUZINSKY R et al.: Efficacy of disulfiram for cocaine abuse in methadone patients: relevance of dopamine beta-hydroxylase. Presented at: the 43rd American College of Neuropsychopharmacology (ACNP) meeting. San Juan, Puerto Rico (2004).
43. CUBELLS JF, ZABETIAN CP: Human genetics of plasma dopamine β-hydroxylase activity: applications to research in psychiatry and neurology. Psychopharmacology (Berl) (2004) 174(4):463-476.
44. BLANCHET PJ, METMAN LV, CHASE TN: Renaissance of amantadine in the treatment of Parkinson's disease. Adv. Neurol. (2003) 91:251-257.
45. CROSBY N, DEANE KH, CLARKE CE: Amantadine in Parkinson's disease. Cochrane Database Syst. Rev. (2003) 1:CD003468.
46. HEIMANS RL, RAND MJ, FENNESSY MR: Effects of amantadine on uptake and release of dopamine by a particulate fraction of rat basal ganglia. J. Pharm. Pharmacol. (1972) 24(11):875-879.
47. STOOF JC, BOOIJ J, DRUKARCH B, WOLTERS EC: The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur. J. Pharmacol. (1992) 213(3):439-443.
48. NASTUK WL, SU P, DOUBILET P: Anticholinergic and membrane activities of amantadine in neuromuscular transmission. Nature (1976) 264(5581):76-79.
49. KAMPMAN K, VOLPICELLI JR, ALTERMAN A et al.: Amantadine in the early treatment of cocaine dependence: a double-blind, placebo-controlled trial. Drug Alcohol Depend. (1996) 41(1):25-33.
50. KAMPMAN KM, VOLPICELLI JR, ALTERMAN AI, CORNISH J, O'BRIEN CP: Amantadine in the treatment of cocaine-dependent patients with severe withdrawal symptoms. Am. J. Psychiatry (2000) 157(12):2052-2054.
51. GIBBS JW, 3RD, SOMBATI S, DELORENZO RJ, COULTER DA: Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia (2000) 41(Suppl. 1):S10-S16.
52. HERRERO AI, DEL OLMO N, GONZALEZ-ESCALADA JR, SOLIS JM: Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology (2002) 42(2):210-220.
53. SHANK RP, GARDOCKI JR STREETER AJ, MARYANOFF BE: An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia (2000) 41(Suppl. 1):S3-S9.
54. KAMPMAN KM, PETTINATI H, LYNCH KG et al.: A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. (2004) 75(3):233-240.
55. SOUDIJN W, VAN WIJNGAARDEN I: The GABA transporter and its inhibitors. Curr. Med. Chem. (2000) 7(10):1063-1079.
56. SCHACHTER SC: Pharmacology and clinical experience with tiagabine. Expert Opin. Pharmacother. (2001) 2(1):179-187.
57. LILE JA, STOOPS WW, GLASER PE, HAYS LR, RUSH CR: Acute administration of the GABA reuptake inhibitor tiagabine does not alter the effects of oral cocaine in humans. Drug Alcohol Depend. (2004) 76(1):81-91.
58. SOFUOGLU M, MITCHELL E, KOSTEN TR: Effects of tiagabine treatment on cocaine responses in cocaine users. Pharmacol. Biochem. Behav. (2005) (in press).
59. GONZALEZ G, SEVARINO K, SOFUOGLU M et al.: Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction (2003) 98(11):1625-1632.
60. LEIDERMAN DB, SHOPTAW S, MONTGOMERY A et al.: Cocaine Rapid Efficacy Screening Trial (CREST): a paradigm for the controlled evaluation of candidate medications for cocaine dependence. Addiction (2005) 1:1-11.
61. WINHUSEN TM, SOMOZA EC, HARRERJM et al.: A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction (2005) 1:68-77.
62. MISGELD U, BIJAK M, JAROLIMEK W: A physiological role for GABAB receptors and the effects of baclofen in the mammalian central nervous system. Prog. Neurobiol. (1995) 46(4):423-462.
63. SHOPTAW S, YANG X, ROTHERAM-FULLER EJ et al.: Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J. Clin. Psychiatry (2003) 64:1440-1448.
64. KAMPMAN KM, VOLPICELLI JR, MULVANEY F et al.: Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol Depend. (2001) 63(1):69-78.
65. SOFUOGLU M, BROWN S, BABB DA, PENTEL PR, HATSUKAMI DK: Effects of labetalol treatment on the physiological and subjective response to smoked cocaine. Pharmacol. Biochem. Behav. (2000) 65(2):255-259.
66. SOFUOGLU M, BROWN S, BABB DA, PENTEL PR, HATSUKAMI DK: Carvedilol affects the physiological and behavioral response to smoked cocaine in humans. Drug Alcohol Depend. (2000) 60(1):69-76.
67. JASINSKI DR: An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J. Psychopharmacol. (2000) 14(1):53-60.
68. RUSH CR, KELLY TH, HAYS LR, BAKER RW, WOOTEN AF: Acute behavioral and physiological effects of modafinil in drug abusers. Behav. Pharmacol. (2002) 13(2):105-115.
69. TANEJA I, DIEDRICH A, BLACK BK et al.: Modafinil elicits sympathomedullary activation. Hypertension (2005) 45(4):612-618.
70. FERRARO L, ANTONELLI T, O'CONNOR WT et al.: The effects of modafinil on striatal, pallidal and nigtal GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci. Lett. (1998) 253(2):135-138.
71. FERRARO L, ANTONELLI T, TANGANELLI S et al.: The vigilance promoting drug modafinit increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology (1999) 20(4):346-356.
72. DACKIS CA, LYNCH KG, YU E et al.: Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Akohol Depend. (2003) 70(1):29-37.
73. DACKIS CA, KAMPMAN KM, LYNCH KG, PETTINATI HM, O'BRIEN CP: A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology (2005) 30(1):205-211.
74. GRABOWSKI J, ROACHE JD, SCHMITZ JM et al.: Replacement medication for cocaine dependence: methylphenidate. J. Clin. Psychopharmacol. (1997) 17(6):485-488.
75. ROACHE JD, GRABOWSKI J, SCHMITZ JM, CRESON DL, RHOADES HM: Laboratory measures of methylphenidate effects in cocaine-dependent patients receiving treatment. J. Clin. Psychopharmacol. (2000) 20(1):61-68.
76. GRABOWSKI J, RHOADES H, STOTTS A et al.: Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacohgy (2004) 29(5):969-981.
77. SHEARER J, WODAK A, VAN BEEK I, MATTICK RP, LEWIS J: Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction (2003) 98(8):1137-1141.
78. HANEY M, KOSTEN TR: Therapeutic vaccines for substance dependence. Expert Rev. Vaccines (2004) 3(1):11-18.
79. KANTAK KM, COLLINS SL, LIPMAN EG et al.: Evaluation of anticocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (2000) 148(3):251-262.
80. KOSTEN TR, ROSEN M, BOND J et al.: Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine (2002) 20(7-8): 1196-1204.
81. MARTELL BA, E. M, POLING J, GONSAI K, KOSTEN TR: Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol. Psychiatry (2005) 58(2):158-164.
82. GLOWA JR, WOJNICKI FH: Effects of drugs on food- and cocaine-maintained responding, III: dopaminergic antagonists. Psychopharmacology (1996) 128(4):351-358.
83. CARROLL FE: Design and development of pharmacotherapies and pharmacological tools for subsrance abuse. Presented at: AAPS - NIDA Symposium Frontiers in Science: Drug Addiction - From Basic Research to Therapies. Bethesda, Maryland, US (2004).
84. HEIDBREDER C: Recent advances in the pharmacotherapeutic management of drug dependence and addiction. (2005) 1:45-67.
85. POLING J, ROUNSAVILLE BJ, BALL S et al.: Rates of personality disorders in substance abusers: a comparison between DSM-III-R and DSM-IV. J. Pen. Disord. (1999) 13(4):375-384.
86. CARROLL KM, NICH C, ROUNSAVILLE BJ: Variability in treatment-seeking cocaine abusers: implications for clinical pharmacotherapy trials. NIDA Res. Monogr. (1997) 175:137-157.
87. SOFUOGLU M, GONZALEZ G, POLING J, KOSTEN TR: Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence. Am. J. Drug Alcohol Abuse (2003) 29(4):713-727.
88. GONZALEZ G, FEINGOLD A, OLIVETO A, GONSAI K, KOSTEN TR: Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management. Am. J. Drug Alcohol Abuse (2003) 29(3):497-514.
89. DE LIMA MS, DE OLIVEIRA SOARES BG, REISSER AA, FARRELL M: Pharmacological treatment of cocaine dependence: a systematic review. Addiction (2002) 97(8):931-949.
90. CONE EJ, DICKERSON SL: Efficacy of urinalysis in monitoring heroin and cocaine abuse patterns: implications in clinical trials for treatment of drug dependence. NIDA Research Monograph (1992) 128:46-58.